Skin checks in Australian general practice: what Medicare covers

In Australia, a skin check almost always starts with the GP, not a dermatologist referral: general practice is the country’s default entry point for finding skin cancer, and it carries the highest melanoma rate recorded anywhere in the world. Australian Medicare does not fund a stand-alone “skin check” item — a routine check is billed the same way as any other consultation, and the dedicated Medicare Benefits Schedule (MBS) items only switch on once a lesion is actually biopsied or cut out. Whether that visit costs the patient anything on the day comes down to one thing: the clinic’s own bulk billing policy, not a skin-cancer-specific rule.

That question is live right now on the New South Wales Far South Coast, where a Health Check Convoy is visiting four towns — Moruya, Bermagui, Bega and Eden — with free walk-in skin-check days in the first week of August, timed to a coastal population with heavy year-round sun exposure. Days like that are good for reach: they catch whoever is worried enough to queue up. They are not, on their own, the system Australia relies on to find skin cancer early — that system is general practice, working case by case.

Australia’s melanoma rate is the highest recorded anywhere, and general practice absorbs the caseload

Cancer Council Australia, drawing on Australian Institute of Health and Welfare data, puts Australia’s age-standardised melanoma incidence rate at 36.6 per 100,000 in 2020 — the highest of any country measured — while its mortality rate ranks only equal sixth in the world. Worst for incidence but not for mortality is itself informative: more melanoma is found here than anywhere else, and much of it is found early enough to treat.

The two leading Australian bodies that publish annual toll figures do not agree on the number, and the gap is worth sitting with rather than smoothing over. Cancer Council Australia cites registry-confirmed counts of 15,628 new melanoma diagnoses in 2019 and 1,455 deaths in 2021. Melanoma Institute Australia instead publishes a rolling estimate — “16,800 Australians will be diagnosed with melanoma this year,” with roughly 1,300 deaths — updated annually as a forward projection rather than a closed historical count. Neither figure is wrong; one looks backward at confirmed cases, the other projects the current year. What both agree on is scale: at least two in three Australians will be diagnosed with some form of skin cancer in their lifetime.

Melanoma gets the headlines, but it is not what fills a GP’s afternoon. The RACGP’s Australian Journal of General Practice puts GPs “at the front line of skin cancer detection,” recording more than one million patient consultations a year for skin cancer between them. Cancer Council Australia adds the volume behind that: more than 1.1 million Medicare-funded services were billed for non-melanoma (keratinocyte) skin cancer treatment in 2022 alone. Melanoma is the disease general practice is built to catch early; keratinocyte cancer is the caseload that books out the day.

There is no national skin cancer screening program, so the GP does risk-based case-finding instead

Australia runs organised national screening programs for bowel, breast and cervical cancer. It does not run one for skin cancer, despite skin cancer being the most commonly diagnosed cancer type in the country. The Conversation, written by dermatology and cancer-epidemiology researchers at the University of Queensland and the University of Sydney, states it plainly: “Australian clinical practice guidelines and health authorities do not recommend screening for melanoma in the general population.” The model instead is risk stratification, and the RACGP names the job explicitly as one that “largely falls within the realm of primary care to stratify and understand which patients require routine checks in accordance with their presenting risk factors” — fair skin type, red hair, family history, more than 100 moles, more than 20 solar keratoses, immunosuppression and heavy outdoor exposure all move a patient up the list.

Uptake reflects that this is opportunistic, not systematic: The Conversation reports that only about one in three Australian adults had a clinical skin check in the past year — not because the system failed the other two-thirds, but because it was never built to check everyone on a fixed clock. A funded response is in motion but not yet live: the Australian Government has committed about $10 million toward a roadmap for a national targeted skin cancer screening program, led by Melanoma Institute Australia with the Australian Institute of Health and Welfare handling the data collection and monitoring work, aimed at high-risk groups rather than the whole population. Until that roadmap becomes a program, general practice is not a supplement to skin cancer screening in Australia — it is the entire system.

Bulk billing decides whether the visit costs anything at all

Because there is no dedicated MBS item for a skin check, the appointment is billed under the same standard consultation item as any other GP visit. So the question patients actually care about — will this cost me anything? — is not answered by a cancer-specific Medicare rule. It is answered by the clinic’s ordinary bulk billing policy for that appointment, on that day, for that patient.

That policy has been moving. Department of Health data, reported by InSight+, the Medical Journal of Australia’s news arm, shows 81.4% of GP services nationally were bulk billed between November 2025 and January 2026, up from 77.1% over the same months a year earlier. InSight+ does not oversell the shift: it is recent enough that “it’s too early to tell for sure” whether the gain holds, and the same piece raises a structural objection — extending bulk billing incentives to every patient regardless of income, rather than targeting disadvantage specifically, is unusual among high-income health systems and, in its words, risks propping up “a dysfunctional funding model” rather than fixing it. A rising national average is real, but it says nothing about whether any one clinic, on any one day, will bulk bill a given skin check.

Medicare funds what a skin check finds, not the check itself

The consultation is only the first rung. Once a GP finds a lesion worth sampling, a diagnostic biopsy sits under its own item, 30071, billable once the specimen goes for pathological examination. If pathology confirms malignancy, excision moves onto a separate ladder of items set by the lesion’s size and where it sits on the body. Item 31356, for example, covers definitive surgical excision of a confirmed malignant lesion under 6mm from a sensitive site — nose, eyelid, eyebrow, lip, ear, digit or genitalia — with a schedule fee of $264.90, and it explicitly requires that “malignancy is confirmed” before the benefit applies. Larger lesions, other body sites and clinically suspected melanoma each sit under their own item numbers again, running from the low 31300s past 31380.

The same visit, in other words, can be funded three different ways depending on what the GP finds — and a patient’s assumption that “the skin check is bulk billed” does not automatically extend past the first stage.

High-risk patients need a standing recall, not one good visit

The RACGP’s own recommendation is specific enough to schedule against: patients it classifies as high-risk should self-check every three to four months and see a GP every six to twelve, against a once-a-year self-check for everyone else. Identifying who belongs in the high-risk group is a clinical judgment a GP makes once. Getting that same patient back in six to twelve months without relying on them to remember is not a clinical problem — it is an administrative one, and it is exactly where a standing recall system earns its keep.

It is also where a one-off public event cannot substitute for a clinic’s own list. A free walk-in day, like the ones running across the Far South Coast in early August, reaches whoever is already concerned enough to turn up. It does nothing for the patient a clinic already knows has more than 100 moles and a family history, last seen fourteen months ago with no reason to think that appointment is overdue unless the clinic says so. Building that kind of standing recall into ordinary scheduling, rather than leaving it to memory on either side of the desk, is the same operational question covered in how general practice runs day to day in Australia.

What your clinic can do

• Tag high-risk patients the moment risk is identified, not at their next booking. Fitzpatrick skin type, family history, mole count and outdoor occupation are all known at the first visit where they come up — flag it then, rather than relying on a future GP to notice it again from the notes.
• Set the recall interval the RACGP actually recommends, not a generic annual default. Six to twelve months for high-risk patients is a materially tighter loop than the once-a-year self-check that is appropriate for everyone else, and treating both groups the same under-serves the ones who need the shorter loop.
• Say the billing stage out loud before it changes, not during the appointment. Because the item — and the benefit — genuinely changes between a consultation, a biopsy and a confirmed excision, a patient who assumed “bulk billed” covers all three can be caught off guard exactly when they are least prepared for it.
• Check scope of practice before delegating any part of the visual check. If a nurse or an allied step handles the first pass, confirm what sits within their AHPRA-registered scope before it feeds into a GP’s decision to biopsy or excise — the judgment call stays medical even when the workflow around it doesn’t.
• Treat community screening days as reach, not as your recall system. They bring in people who were not already on a list. They do nothing for the high-risk patients already on yours who are overdue.